Archive

Press releases

Precirix to present clinical study results of its HER2-targeting CAM-H2 compound at the 2024 SNMMI annual meeting

Tom Plitz commences role as Chief Executive Officer of Precirix

Precirix appoints leading radiopharmaceutical and oncology experts to newly formed Scientific Advisory Board

Precirix announces key leadership appointments

CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US

Precirix enters into collaboration with Eckert & Ziegler for the development of its 68Ga-based compounds

Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225

Precirix presents preclinical data of its FAP-targeting compound

Precirix strengthens patent portfolio

Precirix raises EUR 80m in Series B

Dimitrios Mantzilas joins Precirix as CTO

Precirix dosed first patients in Phase I/II clinical study

Precirix and IFE sign clinical trial manufacturing agreement

Precirix enters into alliance with 3P Biopharmaceuticals for the manufacturing of single domain antibodies

Precirix partners with Evergreen to expand North American clinical trial supply

Dr. Niva Almaula joins Precirix as Chief Business Officer

Camel-IDS enters next stage with name change to PRECIRIX® and IND approval

Dr. Matthias Friebe joins as acting Chief Technology Officer

Ruggero Della Bitta MD, PhD, appointed Chief Medical Officer

Camel-IDS appoints Thomas Ramdahl as Independent Director

Camel-IDS completes EUR 37m Series A financing to develop cancer-targeted radiopharmaceuticals

Media features

Science Director, Matthias D'Huyvetter, provides insight in Precirix' activities

Belgium’s Camel-IDS reels in €37M to push breast cancer radiotherapy

Geld uit vijf landen voor Brussels biotechbedrijf (De Standaard)

37 miljoen om kanker met kamelen te bestrijden (De Tijd)

Brussels biotechbedrijf Camel-IDS haalt 37 miljoen euro op (Trends)

Camel-IDS explose les plafonds biotech et lève 37 millions (L'Echo)

Kanker bestrijden met elektrische fietsjes in het bloed

Events

2022 ASCO Annual Meeting

Your browser is not supported. Update your browser for more security, speed and to make the most of this site.